phenobarbital has been researched along with Canine Diseases in 123 studies
Phenobarbital: A barbituric acid derivative that acts as a nonselective central nervous system depressant. It potentiates GAMMA-AMINOBUTYRIC ACID action on GABA-A RECEPTORS, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations.
phenobarbital : A member of the class of barbiturates, the structure of which is that of barbituric acid substituted at C-5 by ethyl and phenyl groups.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Imepitoin was tested as a combination treatment with phenobarbital in an open-label mono-centre cohort study in dogs with drug-resistant epilepsy." | 9.24 | Clinical evaluation of a combination therapy of imepitoin with phenobarbital in dogs with refractory idiopathic epilepsy. ( Keefe, T; Kostic, D; Löscher, W; Neßler, J; Rundfeldt, C; Tipold, A, 2017) |
| "To assess tolerability and short-term efficacy of oral administration of pregabalin as an adjunct to phenobarbital, potassium bromide, or a combination of phenobarbital and potassium bromide for treatment of dogs with poorly controlled suspected idiopathic epilepsy." | 9.14 | Pregabalin as an adjunct to phenobarbital, potassium bromide, or a combination of phenobarbital and potassium bromide for treatment of dogs with suspected idiopathic epilepsy. ( Badgley, BL; Cerda-Gonzalez, S; Cooper, JJ; Dewey, CW; Ducoté, JM; Lavely, JA; Levine, JM; Packer, RA; Silver, GM, 2009) |
| "To investigate caregivers' assessments of outcome in dogs with idiopathic epilepsy (IE) administered levetiracetam (LEV), zonisamide (ZNS), or phenobarbital (PB) monotherapy." | 8.31 | Comparison of caregivers' assessments of clinical outcome in dogs with idiopathic epilepsy administered levetiracetam, zonisamide, or phenobarbital monotherapy. ( Gristina, BR; Muñana, KR; Nettifee, JA; Waldron, RJ, 2023) |
| " Bernard-mastiff crossbred dog showed clinical signs of lethargy and anorexia after being administered phenobarbital for the treatment of idiosyncratic seizures." | 8.02 | Pancytopenia secondary to suspected idiosyncratic phenobarbital reaction in a dog. ( Oberholster, O, 2021) |
| " The cause of recurrent gastrointestinal signs following the initial successful treatment of phenobarbital-responsive sialadenosis was due to oesophageal stricture formation." | 8.02 | Successful treatment of a dog with phenobarbital-responsive sialadenosis and an oesophageal stricture. ( Chae, HK; Choi, MC; Lee, JH; Song, WJ; Youn, HY, 2021) |
| "The aim of this study was to evaluate changes in epileptic seizures (ES) frequency and semiology in antiepileptic-medication (AEM)-naïve dogs with idiopathic epilepsy (DIE) after initiation of imepitoin (IMP) or phenobarbital (PB) monotherapy." | 7.91 | Epileptic seizure frequency and semiology in dogs with idiopathic epilepsy after initiation of imepitoin or phenobarbital monotherapy. ( Barnett, CR; De Risio, L; Stabile, F; van Dijk, J, 2019) |
| "Phenobarbital or potassium bromide (KBr) add-on treatment decreases the average monthly seizure frequency in dogs with idiopathic epilepsy resistant to a maximum dose of imepitoin." | 7.85 | Imepitoin withdrawal in dogs with idiopathic epilepsy well-controlled with imepitoin and phenobarbital and/or potassium bromide does not increase seizure frequency. ( Bhatti, SFM; Broeckx, BJG; Martlé, V; Royaux, E; Stee, K; Van Ham, L, 2017) |
| " Seizures were controlled with phenobarbital (6 mg/kg IM q 12 h) and propofol CRI (0." | 7.83 | Successful treatment of refractory seizures with phenobarbital, propofol, and medetomidine following congenital portosystemic shunt ligation in a dog. ( Giordano, P; Heidenreich, DC; Kirby, BM, 2016) |
| "-6-180T>G) associated with resistance to phenobarbital therapy has been found in the canine MDR1/ABCB1 gene in Border Collies with idiopathic epilepsy." | 7.79 | High frequency of a single nucleotide substitution (c.-6-180T>G) of the canine MDR1/ABCB1 gene associated with phenobarbital-resistant idiopathic epilepsy in Border Collie dogs. ( Chang, HS; Kohyama, M; Kushida, K; Mizukami, K; Rahman, MM; Uddin, MM; Yabuki, A; Yamato, O, 2013) |
| "The failure of the maximum tolerated dosage to improve seizure control in dogs with phenobarbital-resistant epilepsy argues against the suitability of verapamil add-on treatment to overcome pharmacoresistance." | 7.77 | Add-on treatment with verapamil in pharmacoresistant canine epilepsy. ( Jambroszyk, M; Potschka, H; Tipold, A, 2011) |
| "To describe outcome of treatment with propofol and phenobarbital for status epilepticus (SE) after portosystemic shunt (PSS) attenuation." | 7.76 | Outcome from status epilepticus after portosystemic shunt attenuation in 3 dogs treated with propofol and phenobarbital. ( Claeys, S; Daminet, S; de Rooster, H; Gommeren, K; Hamaide, A, 2010) |
| ", fasting concentrations) in dogs with epilepsy that had been treated long term (> or = 3 months) with phenobarbital or with phenobarbital and potassium bromide with concentrations in healthy control dogs." | 7.74 | Serum triglyceride concentration in dogs with epilepsy treated with phenobarbital or with phenobarbital and bromide. ( Govendir, M; Ilkin, WJ; Kluger, EK; Malik, R; Snow, D; Sullivan, DR, 2008) |
| "To assess whether there is a change in seizure activity in dogs with refractory epilepsy that are receiving appropriate doses of phenobarbitone and/or potassium bromide, when gabapentin is added to the therapeutic regimen." | 7.73 | Improving seizure control in dogs with refractory epilepsy using gabapentin as an adjunctive agent. ( Govendir, M; Malik, R; Perkins, M, 2005) |
| "Questionnaires were mailed to owners of 29 dogs under management for suspected or diagnosed idiopathic epilepsy through the clinics of the Small Animal Hospital of the University of Glasgow Veterinary School, using either phenobarbitone or potassium bromide alone or in combination." | 7.73 | Idiopathic epilepsy in dogs: owners' perspectives on management with phenobarbitone and/or potassium bromide. ( Anderson, TJ; Chang, Y; Mellor, DJ, 2006) |
| "Bromide toxicosis was diagnosed in an 8-year-old Labrador Retriever that had been treated for epilepsy with potassium bromide, at a dosage of 29 mg/kg of body weight/d." | 7.69 | Bromide toxicosis secondary to renal insufficiency in an epileptic dog. ( Linn, K; Nichols, ES; Trepanier, LA, 1996) |
| "The efficacy of phenobarbital and primidone against canine epilepsy was compared in a controlled study." | 7.67 | Therapeutic efficacy of phenobarbital and primidone in canine epilepsy: a comparison. ( Frey, HH; Löscher, W; Schwartz-Porsche, D, 1985) |
| "Dogs that experienced no additional seizures were defined as responders, whereas those that showed additional seizure activity were classified as nonresponders." | 6.90 | Open-label clinical trial of rectally administered levetiracetam as supplemental treatment in dogs with cluster seizures. ( Bellino, C; Bertone, I; Cagnotti, G; Corona, C; D'Angelo, A; Dappiano, E; Gardini, G; Iulini, B; Odore, R, 2019) |
| "Five phenobarbital treated dogs were classified as true responders (≥50% reduction in seizures/month) whereas none of the levetiracetam treated dogs fulfilled this criterion." | 6.82 | A single-blinded phenobarbital-controlled trial of levetiracetam as mono-therapy in dogs with newly diagnosed epilepsy. ( Berendt, M; Fredsø, N; Møller, A; Sabers, A; Toft, N, 2016) |
| "In phenobarbital-treated dogs, significantly increased levels of alkaline phosphatase, gamma-glutamyl-transferase and other liver enzymes occurred, while no such effect was observed in the imepitoin group." | 6.80 | Clinical efficacy and safety of imepitoin in comparison with phenobarbital for the control of idiopathic epilepsy in dogs. ( de Vries, F; Keefe, TJ; Löscher, W; Rundfeldt, C; Tipold, A, 2015) |
| "Phenobarbital treatment resulted in eradication of seizures (17/20 [85%]) significantly more often than did bromide (12/23 [52%]); phenobarbital treatment also resulted in a greater percentage decrease in seizure duration (88 ± 34%), compared with bromide (49 ± 75%)." | 5.38 | Comparison of phenobarbital with bromide as a first-choice antiepileptic drug for treatment of epilepsy in dogs. ( Boothe, DM; Carpenter, DM; Dewey, C, 2012) |
| "To determine whether there are therapeutically relevant changes in serum phenobarbital concentrations throughout a daily dosing interval in epileptic dogs receiving phenobarbital for > or = 3 weeks." | 5.31 | Effect of timing of blood collection on serum phenobarbital concentrations in dogs with epilepsy. ( Levitski, RE; Trepanier, LA, 2000) |
| " Serum concentrations differed even with the same dosage among individual dogs." | 5.28 | [Effectiveness of bromide in therapy resistant epilepsy of dogs]. ( Jürgens, U; Schwartz-Porsche, D, 1991) |
| " Further, for dogs given phenobarbital, there was a sixfold variation between dosage and achieved serum concentration, whereas dogs given primidone manifested even greater variability between dosage and serum concentration." | 5.27 | Serum concentrations and efficacy of phenytoin, phenobarbital, and primidone in canine epilepsy. ( Farnbach, GC, 1984) |
| "Imepitoin was tested as a combination treatment with phenobarbital in an open-label mono-centre cohort study in dogs with drug-resistant epilepsy." | 5.24 | Clinical evaluation of a combination therapy of imepitoin with phenobarbital in dogs with refractory idiopathic epilepsy. ( Keefe, T; Kostic, D; Löscher, W; Neßler, J; Rundfeldt, C; Tipold, A, 2017) |
| "To assess tolerability and short-term efficacy of oral administration of pregabalin as an adjunct to phenobarbital, potassium bromide, or a combination of phenobarbital and potassium bromide for treatment of dogs with poorly controlled suspected idiopathic epilepsy." | 5.14 | Pregabalin as an adjunct to phenobarbital, potassium bromide, or a combination of phenobarbital and potassium bromide for treatment of dogs with suspected idiopathic epilepsy. ( Badgley, BL; Cerda-Gonzalez, S; Cooper, JJ; Dewey, CW; Ducoté, JM; Lavely, JA; Levine, JM; Packer, RA; Silver, GM, 2009) |
| "To investigate caregivers' assessments of outcome in dogs with idiopathic epilepsy (IE) administered levetiracetam (LEV), zonisamide (ZNS), or phenobarbital (PB) monotherapy." | 4.31 | Comparison of caregivers' assessments of clinical outcome in dogs with idiopathic epilepsy administered levetiracetam, zonisamide, or phenobarbital monotherapy. ( Gristina, BR; Muñana, KR; Nettifee, JA; Waldron, RJ, 2023) |
| "Phenobarbital (PB) is the most common antiseizure drug (ASD) used for the management of feline epilepsy." | 4.12 | Evaluation of the effect of phenobarbital administration on the biochemistry profile, with a focus on serum liver values, in epileptic cats. ( Bhatti, SF; Broeckx, BJ; Charalambous, M; Cornelis, I; Eisl-Glantschnigg, U; Hermans, M; Neßler, J; Paepe, D; Pakozdy, A; Serrano, G; Van Ham, L; Van Meervenne, SA, 2022) |
| " Bernard-mastiff crossbred dog showed clinical signs of lethargy and anorexia after being administered phenobarbital for the treatment of idiosyncratic seizures." | 4.02 | Pancytopenia secondary to suspected idiosyncratic phenobarbital reaction in a dog. ( Oberholster, O, 2021) |
| " The cause of recurrent gastrointestinal signs following the initial successful treatment of phenobarbital-responsive sialadenosis was due to oesophageal stricture formation." | 4.02 | Successful treatment of a dog with phenobarbital-responsive sialadenosis and an oesophageal stricture. ( Chae, HK; Choi, MC; Lee, JH; Song, WJ; Youn, HY, 2021) |
| "The aim of this study was to evaluate changes in epileptic seizures (ES) frequency and semiology in antiepileptic-medication (AEM)-naïve dogs with idiopathic epilepsy (DIE) after initiation of imepitoin (IMP) or phenobarbital (PB) monotherapy." | 3.91 | Epileptic seizure frequency and semiology in dogs with idiopathic epilepsy after initiation of imepitoin or phenobarbital monotherapy. ( Barnett, CR; De Risio, L; Stabile, F; van Dijk, J, 2019) |
| "Phenobarbital or potassium bromide (KBr) add-on treatment decreases the average monthly seizure frequency in dogs with idiopathic epilepsy resistant to a maximum dose of imepitoin." | 3.85 | Imepitoin withdrawal in dogs with idiopathic epilepsy well-controlled with imepitoin and phenobarbital and/or potassium bromide does not increase seizure frequency. ( Bhatti, SFM; Broeckx, BJG; Martlé, V; Royaux, E; Stee, K; Van Ham, L, 2017) |
| " The dog was receiving levetiracetam and phenobarbital for epilepsy, and serum concentrations of both were within standard therapeutic ranges." | 3.85 | Suspected Phenobarbital-Induced Pseudolymphoma in a Dog. ( Lampe, R; Manens, J; Sharp, N, 2017) |
| " Seizures were controlled with phenobarbital (6 mg/kg IM q 12 h) and propofol CRI (0." | 3.83 | Successful treatment of refractory seizures with phenobarbital, propofol, and medetomidine following congenital portosystemic shunt ligation in a dog. ( Giordano, P; Heidenreich, DC; Kirby, BM, 2016) |
| "-6-180T>G) associated with resistance to phenobarbital therapy has been found in the canine MDR1/ABCB1 gene in Border Collies with idiopathic epilepsy." | 3.79 | High frequency of a single nucleotide substitution (c.-6-180T>G) of the canine MDR1/ABCB1 gene associated with phenobarbital-resistant idiopathic epilepsy in Border Collie dogs. ( Chang, HS; Kohyama, M; Kushida, K; Mizukami, K; Rahman, MM; Uddin, MM; Yabuki, A; Yamato, O, 2013) |
| "The failure of the maximum tolerated dosage to improve seizure control in dogs with phenobarbital-resistant epilepsy argues against the suitability of verapamil add-on treatment to overcome pharmacoresistance." | 3.77 | Add-on treatment with verapamil in pharmacoresistant canine epilepsy. ( Jambroszyk, M; Potschka, H; Tipold, A, 2011) |
| "To describe outcome of treatment with propofol and phenobarbital for status epilepticus (SE) after portosystemic shunt (PSS) attenuation." | 3.76 | Outcome from status epilepticus after portosystemic shunt attenuation in 3 dogs treated with propofol and phenobarbital. ( Claeys, S; Daminet, S; de Rooster, H; Gommeren, K; Hamaide, A, 2010) |
| ", fasting concentrations) in dogs with epilepsy that had been treated long term (> or = 3 months) with phenobarbital or with phenobarbital and potassium bromide with concentrations in healthy control dogs." | 3.74 | Serum triglyceride concentration in dogs with epilepsy treated with phenobarbital or with phenobarbital and bromide. ( Govendir, M; Ilkin, WJ; Kluger, EK; Malik, R; Snow, D; Sullivan, DR, 2008) |
| "Twenty-two dogs with idiopathic epilepsy which were pharmacoresistant to phenobarbitone and bromide were treated with levetiracetam as an add-on medication." | 3.74 | The efficacy and tolerability of levetiracetam in pharmacoresistant epileptic dogs. ( Chandler, KE; Luján Feliu-Pascual, A; Matiasek, LA; Platt, SR; Volk, HA, 2008) |
| "To assess whether there is a change in seizure activity in dogs with refractory epilepsy that are receiving appropriate doses of phenobarbitone and/or potassium bromide, when gabapentin is added to the therapeutic regimen." | 3.73 | Improving seizure control in dogs with refractory epilepsy using gabapentin as an adjunctive agent. ( Govendir, M; Malik, R; Perkins, M, 2005) |
| "Questionnaires were mailed to owners of 29 dogs under management for suspected or diagnosed idiopathic epilepsy through the clinics of the Small Animal Hospital of the University of Glasgow Veterinary School, using either phenobarbitone or potassium bromide alone or in combination." | 3.73 | Idiopathic epilepsy in dogs: owners' perspectives on management with phenobarbitone and/or potassium bromide. ( Anderson, TJ; Chang, Y; Mellor, DJ, 2006) |
| " In a prospective trial in dogs with newly diagnosed epilepsy, ELB 138 markedly reduced seizure frequency and severity without significant difference to standard treatments (phenobarbital or primidone) but was much better tolerated than the standard drugs." | 3.72 | Anticonvulsant efficacy of the low-affinity partial benzodiazepine receptor agonist ELB 138 in a dog seizure model and in epileptic dogs with spontaneously recurrent seizures. ( Löscher, W; Potschka, H; Rieck, S; Rundfeldt, C; Tipold, A, 2004) |
| "A study was undertaken to evaluate owners' perception of the effect that epilepsy and long-term phenobarbital therapy had on the quality of pet and owner lifestyle." | 3.70 | Owner perception of the care of long-term phenobarbital-treated epileptic dogs. ( Lord, LK; Podell, M, 1999) |
| " Sensitivity to phenobarbital and related anticonvulsants may induce life-threatening leukopenia, thrombocytopenia, and anemia in dogs." | 3.70 | Neutropenia and thrombocytopenia in three dogs treated with anticonvulsants. ( Calvert, C; Jacobs, G; Kaufman, A, 1998) |
| "Bromide toxicosis was diagnosed in an 8-year-old Labrador Retriever that had been treated for epilepsy with potassium bromide, at a dosage of 29 mg/kg of body weight/d." | 3.69 | Bromide toxicosis secondary to renal insufficiency in an epileptic dog. ( Linn, K; Nichols, ES; Trepanier, LA, 1996) |
| " Using a PEG 3350 screen combined with detergents, and developed from our experiments with an IgG2a kappa antibody specific for canine lymphoma cells, crystals have now been obtained of two of these four immunoglobulins, an antiphenytoin and an antiphenobarbital antibody." | 3.69 | Crystallization of intact monoclonal antibodies. ( Harris, LJ; McPherson, A; Skaletsky, E, 1995) |
| "Bromide treatment was successful in controlling seizures in an 11-year-old Dachshund with epilepsy and presumptive phenobarbital-associated hepatopathy." | 3.69 | High dietary chloride content associated with loss of therapeutic serum bromide concentrations in an epileptic dog. ( Center, SA; Garland, S; Shaw, N; Trepanier, LA, 1996) |
| "To determine what effects long-term phenobarbital administration to dogs with epilepsy would have on serum biochemical factors and adrenocortical function." | 3.69 | Effects of phenobarbital administration on results of serum biochemical analyses and adrenocortical function tests in epileptic dogs. ( Chauvet, AE; Feldman, EC; Kass, PH, 1995) |
| "The efficacy of phenobarbital and primidone against canine epilepsy was compared in a controlled study." | 3.67 | Therapeutic efficacy of phenobarbital and primidone in canine epilepsy: a comparison. ( Frey, HH; Löscher, W; Schwartz-Porsche, D, 1985) |
| "Fifteen dogs with idiopathic epilepsy were included in a 9-month clinical trial to determine the therapeutic serum concentrations of primidone and its active metabolites, phenobarbital and phenylethylmalonamide." | 3.66 | Therapeutic serum concentrations of primidone and its metabolites, phenobarbital and phenylethylmalonamide in epileptic dogs. ( Cunningham, JG; Haidukewych, D; Jensen, HA, 1983) |
| "Dogs that experienced no additional seizures were defined as responders, whereas those that showed additional seizure activity were classified as nonresponders." | 2.90 | Open-label clinical trial of rectally administered levetiracetam as supplemental treatment in dogs with cluster seizures. ( Bellino, C; Bertone, I; Cagnotti, G; Corona, C; D'Angelo, A; Dappiano, E; Gardini, G; Iulini, B; Odore, R, 2019) |
| "Five phenobarbital treated dogs were classified as true responders (≥50% reduction in seizures/month) whereas none of the levetiracetam treated dogs fulfilled this criterion." | 2.82 | A single-blinded phenobarbital-controlled trial of levetiracetam as mono-therapy in dogs with newly diagnosed epilepsy. ( Berendt, M; Fredsø, N; Møller, A; Sabers, A; Toft, N, 2016) |
| "In phenobarbital-treated dogs, significantly increased levels of alkaline phosphatase, gamma-glutamyl-transferase and other liver enzymes occurred, while no such effect was observed in the imepitoin group." | 2.80 | Clinical efficacy and safety of imepitoin in comparison with phenobarbital for the control of idiopathic epilepsy in dogs. ( de Vries, F; Keefe, TJ; Löscher, W; Rundfeldt, C; Tipold, A, 2015) |
| "Phenobarbitone does not interfere with LDDS testing regardless of dosage or treatment time." | 2.69 | Effect of phenobarbitone on the low-dose dexamethasone suppression test and the urinary corticoid: creatinine ratio in dogs. ( Church, DB; Foster, SF; Watson, AD, 2000) |
| "Idiopathic epilepsy is the most common brain disease in dogs and also occurs in cats." | 2.46 | Idiopathic epilepsy in dogs and cats. ( Thomas, WB, 2010) |
| "Successful treatment of seizure disorders in small animals requires proper patient assessment, understanding the principles of antiepileptic drug (AED) therapy, designing a strategy for pharmacotherapy, and plans for emergency treatment." | 2.40 | Antiepileptic drug therapy. ( Podell, M, 1998) |
| "Idiopathic epilepsy is one of the most common and treatable neurologic diseases of small animals." | 2.40 | Idiopathic epilepsy. ( Knowles, K, 1998) |
| "Sixty-seven dogs (13." | 1.72 | Approach to initial management of canine generalised epileptic seizures in primary-care veterinary practices in the United Kingdom. ( Garosi, L; Green, M; Lowrie, M; McConnell, K; Singleton, D, 2022) |
| "Phenobarbital is a commonly used anticonvulsant for the treatment of canine epileptic seizures." | 1.62 | Serum NMR metabolomics uncovers multiple metabolic changes in phenobarbital-treated dogs. ( Lohi, H; Müller, E; Ottka, C; Weber, C, 2021) |
| " A population pharmacokinetic approach and nonlinear mixed effects modeling were used to analyze the data." | 1.48 | Population pharmacokinetics of extended-release levetiracetam in epileptic dogs when administered alone, with phenobarbital or zonisamide. ( Muñana, KR; Nettifee, JA; Otamendi, AJ; Papich, MG, 2018) |
| "When phenobarbital was administered every eight hours, 9/10 dogs experienced improvement in seizure frequency and 8/10 dogs maintained seizure freedom for a period three times longer than the longest interictal interval period previously recorded." | 1.46 | Phenobarbital administration every eight hours: improvement of seizure management in idiopathic epileptic dogs with decreased phenobarbital elimination half-life. ( Barnett, CR; De Risio, L; Stabile, F, 2017) |
| "Cricopharyngeal dysphagia was diagnosed using fluoroscopy, and non-inflammatory salivary disease was diagnosed using a combination of cytology and computed tomography." | 1.46 | Cricopharyngeal dysphagia and phenobarbitone-responsive sialoadenosis in a Miniature Poodle. ( Lacorcia, L; le Chevoir, M; Mansfield, CS; McCann, S; Wernham, B, 2017) |
| "The aim of this study was to compare ataxia levels in dogs with IE treated chronically with phenobarbitone or imepitoin, the two currently available first-line AED treatments." | 1.43 | Comparing the effects of first-line antiepileptic drugs on the gait of dogs with idiopathic epilepsy. ( Packer, RM; Suiter, EJ; Volk, HA, 2016) |
| "Inflammatory conditions and specifically acute pancreatitis are of major concern in these animals." | 1.42 | Canine Pancreas-Specific Lipase and C-reactive Protein in Dogs Treated With Anticonvulsants (Phenobarbital and Potassium Bromide). ( Albarracín, V; Meléndez-Lazo, A; Pastor, J; Rodón, J; Teles, M, 2015) |
| "Dogs with palliatively treated primary brain tumors, particularly those with tumors in the cerebellum, pons, or medulla, had a poor prognosis." | 1.39 | Survival time following hospital discharge in dogs with palliatively treated primary brain tumors. ( Jones, JC; Robertson, JL; Rossmeisl, JH; Zimmerman, KL, 2013) |
| "A device capable of detecting seizures and alerting caregivers would be a major advance for epilepsy management, and could be used to guide early intervention and prevent seizure-related injuries." | 1.39 | Feasibility study of a caregiver seizure alert system in canine epilepsy. ( Cloyd, JC; Coles, LD; Higgins, J; Leyde, K; Litt, B; Mavoori, J; Michael, B; Patterson, EE; Sheffield, WD; Vite, C; Worrell, GA, 2013) |
| "One dog exhibited increased seizure activity due to a compounded, flavored phenobarbital solution that deteriorated before the expiration date provided by the compounder." | 1.38 | Compounding errors in 2 dogs receiving anticonvulsants. ( Adams, C; McConkey, SE; Walker, S, 2012) |
| "Phenobarbital treatment resulted in eradication of seizures (17/20 [85%]) significantly more often than did bromide (12/23 [52%]); phenobarbital treatment also resulted in a greater percentage decrease in seizure duration (88 ± 34%), compared with bromide (49 ± 75%)." | 1.38 | Comparison of phenobarbital with bromide as a first-choice antiepileptic drug for treatment of epilepsy in dogs. ( Boothe, DM; Carpenter, DM; Dewey, C, 2012) |
| "In the three dogs with porencephaly, there was unilateral incomplete loss of the parietal lobe and one dog had additional partial loss of the temporal and frontal lobes." | 1.38 | Porencephaly and hydranencephaly in six dogs. ( Behr, S; Davies, ES; de Lahunta, A; Garosi, L; Jull, P; Summers, B; Syme, H; Volk, HA, 2012) |
| "Epilepsy is the most common neurological disorder in both dogs and humans." | 1.35 | Positive impact of omega-3 fatty acid supplementation in a dog with drug-resistant epilepsy: a case study. ( Arida, RM; Cavalheiro, EA; Cysneiros, RM; Ribeiro, MO; Scorza, CA; Scorza, FA; Terra, VC, 2009) |
| "In phenobarbital-treated dogs with high serum total AP activity in the cross-sectional study, the increase was due predominantly to increased activities of the corticosteroid-induced (C-AP) and liver (L-AP) isoenzymes." | 1.32 | Serum alkaline phosphatase isoenzyme profiles in phenobarbital-treated epileptic dogs. ( Cribb, AE; Gaskill, CL; Hoffmann, WE, 2004) |
| "To determine whether there are therapeutically relevant changes in serum phenobarbital concentrations throughout a daily dosing interval in epileptic dogs receiving phenobarbital for > or = 3 weeks." | 1.31 | Effect of timing of blood collection on serum phenobarbital concentrations in dogs with epilepsy. ( Levitski, RE; Trepanier, LA, 2000) |
| "Prodromal phase and aura were present in the majority of the dogs with generalised seizures." | 1.30 | Clinical, epidemiological and treatment results of idiopathic epilepsy in 54 labrador retrievers: a long-term study. ( Faissler, D; Heynold, Y; Jaggy, A; Steffen, F, 1997) |
| " When phenobarbital is used in combination with bromide, a reasonable therapeutic range for serum phenobarbital concentrations is 9 to 36 micrograms/ml, although in some dogs treated with bromide, phenobarbital can eventually be discontinued." | 1.30 | Therapeutic serum drug concentrations in epileptic dogs treated with potassium bromide alone or in combination with other anticonvulsants: 122 cases (1992-1996). ( Carrillo, J; Schwark, WS; Trepanier, LA; Van Schoick, A, 1998) |
| "Bromide treatment was not associated with any significant change in these serum thyroid hormone concentrations." | 1.30 | Serum total thyroxine, total triiodothyronine, free thyroxine, and thyrotropin concentrations in epileptic dogs treated with anticonvulsants. ( Kantrowitz, LB; Melián, C; Nichols, R; Peterson, ME; Trepanier, LA, 1999) |
| "Medical records were reviewed for seizure and medication history, diagnostic test results, types of treatment, hospitalization costs, and outcome of hospital visits." | 1.30 | Clinical findings, treatment, and outcome of dogs with status epilepticus or cluster seizures: 156 cases (1990-1995). ( Bateman, SW; Parent, JM, 1999) |
| " Individual optimal drug dosage can be calculated for each patient at little cost to the pet owner." | 1.30 | Drug choice and therapeutic drug monitoring in the management of canine primary epilepsy. ( Taylor, JH; Vaughan-Scott, T, 1999) |
| "Treatment with phenobarbital was effective in 5 of 7 dogs." | 1.29 | Behavioral changes associated with suspected complex partial seizures in bull terriers. ( Dodman, NH; Keen, CL; Knowles, KE; Moon-Fanelli, AA; Shuster, L; Tidwell, AS, 1996) |
| " Serum concentrations differed even with the same dosage among individual dogs." | 1.28 | [Effectiveness of bromide in therapy resistant epilepsy of dogs]. ( Jürgens, U; Schwartz-Porsche, D, 1991) |
| " Serum concentrations of phenobarbital were measured in all dogs before and after primidone therapy was initiated, to ensure that the primidone dosage achieved comparable or higher values when derived from primidone." | 1.27 | Efficacy of primidone in dogs with seizures unresponsive to phenobarbital. ( Farnbach, GC, 1984) |
| " Further, for dogs given phenobarbital, there was a sixfold variation between dosage and achieved serum concentration, whereas dogs given primidone manifested even greater variability between dosage and serum concentration." | 1.27 | Serum concentrations and efficacy of phenytoin, phenobarbital, and primidone in canine epilepsy. ( Farnbach, GC, 1984) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 14 (11.38) | 18.7374 |
| 1990's | 25 (20.33) | 18.2507 |
| 2000's | 34 (27.64) | 29.6817 |
| 2010's | 41 (33.33) | 24.3611 |
| 2020's | 9 (7.32) | 2.80 |
| Authors | Studies |
|---|---|
| Oberholster, O | 1 |
| Green, M | 1 |
| Lowrie, M | 1 |
| Singleton, D | 1 |
| Garosi, L | 2 |
| McConnell, K | 1 |
| Gristina, BR | 1 |
| Waldron, RJ | 1 |
| Nettifee, JA | 2 |
| Muñana, KR | 3 |
| Basile, JK | 1 |
| Vigani, A | 1 |
| Chae, HK | 1 |
| Lee, JH | 1 |
| Choi, MC | 1 |
| Song, WJ | 1 |
| Youn, HY | 1 |
| Scott, TN | 1 |
| Bailin, HG | 1 |
| Jutkowitz, LA | 1 |
| Scott, MA | 1 |
| Lucidi, CA | 1 |
| Ottka, C | 1 |
| Weber, C | 1 |
| Müller, E | 1 |
| Lohi, H | 1 |
| Barry, M | 1 |
| Cameron, S | 1 |
| Kent, S | 1 |
| Barnes-Heller, H | 1 |
| Grady, K | 1 |
| Hermans, M | 1 |
| Charalambous, M | 1 |
| Pakozdy, A | 1 |
| Eisl-Glantschnigg, U | 1 |
| Neßler, J | 2 |
| Van Meervenne, SA | 1 |
| Serrano, G | 1 |
| Cornelis, I | 3 |
| Van Ham, L | 5 |
| Paepe, D | 1 |
| Broeckx, BJ | 2 |
| Bhatti, SF | 2 |
| McCann, S | 1 |
| le Chevoir, M | 1 |
| Lacorcia, L | 1 |
| Wernham, B | 1 |
| Mansfield, CS | 1 |
| Lampe, R | 1 |
| Manens, J | 1 |
| Sharp, N | 1 |
| Stee, K | 1 |
| Martlé, V | 1 |
| Broeckx, BJG | 1 |
| Royaux, E | 2 |
| Bhatti, SFM | 1 |
| Otamendi, AJ | 1 |
| Papich, MG | 1 |
| de Bairros, AV | 1 |
| Dias, D | 1 |
| Bezerra, A | 1 |
| Wagner, R | 1 |
| Klein, B | 1 |
| Kommers, G | 1 |
| Stefanon, E | 1 |
| Miguel Pego, A | 1 |
| Cagnotti, G | 1 |
| Odore, R | 1 |
| Bertone, I | 1 |
| Corona, C | 1 |
| Dappiano, E | 1 |
| Gardini, G | 1 |
| Iulini, B | 1 |
| Bellino, C | 1 |
| D'Angelo, A | 1 |
| Stabile, F | 2 |
| van Dijk, J | 1 |
| Barnett, CR | 2 |
| De Risio, L | 3 |
| Coles, LD | 1 |
| Patterson, EE | 1 |
| Sheffield, WD | 1 |
| Mavoori, J | 1 |
| Higgins, J | 1 |
| Michael, B | 1 |
| Leyde, K | 1 |
| Cloyd, JC | 1 |
| Litt, B | 1 |
| Vite, C | 1 |
| Worrell, GA | 1 |
| Penderis, J | 2 |
| Volk, H | 1 |
| Mizukami, K | 1 |
| Yabuki, A | 1 |
| Chang, HS | 1 |
| Uddin, MM | 1 |
| Rahman, MM | 1 |
| Kushida, K | 1 |
| Kohyama, M | 1 |
| Yamato, O | 1 |
| Böhm, M | 1 |
| Henderson, H | 1 |
| Van der Zwan, H | 1 |
| Basson, S | 1 |
| Bersan, E | 1 |
| Volk, HA | 4 |
| Ros, C | 1 |
| Tipold, A | 4 |
| Keefe, TJ | 1 |
| Löscher, W | 5 |
| Rundfeldt, C | 3 |
| de Vries, F | 1 |
| Thomson, C | 1 |
| Alcoverro, E | 1 |
| Tabar, MD | 1 |
| Lloret, A | 1 |
| Roura, X | 1 |
| Pastor, J | 2 |
| Planellas, M | 1 |
| Simerdova, V | 1 |
| Hajek, I | 1 |
| Schanilec, P | 1 |
| Moore, AR | 1 |
| Chu, C | 1 |
| Singh, K | 1 |
| Barger, AM | 1 |
| Schnelle, AN | 1 |
| Albarracín, V | 1 |
| Teles, M | 1 |
| Meléndez-Lazo, A | 1 |
| Rodón, J | 1 |
| Fredsø, N | 1 |
| Sabers, A | 1 |
| Toft, N | 1 |
| Møller, A | 1 |
| Berendt, M | 1 |
| Kees, M | 1 |
| Beckel, N | 1 |
| Sharp, C | 1 |
| Heidenreich, DC | 1 |
| Giordano, P | 1 |
| Kirby, BM | 1 |
| Fraser, AR | 1 |
| le Chevoir, MA | 1 |
| Long, SN | 1 |
| Vandenabeele, S | 1 |
| Dunon, D | 1 |
| Bossens, K | 1 |
| Daminet, S | 3 |
| Duchateau, L | 1 |
| Rick, M | 1 |
| Bhatti, S | 1 |
| Suiter, EJ | 1 |
| Packer, RM | 1 |
| Bosseler, L | 1 |
| Defauw, P | 1 |
| Ducatelle, R | 1 |
| Kostic, D | 1 |
| Keefe, T | 1 |
| Van Soens, I | 1 |
| Gielen, I | 1 |
| Deforce, D | 1 |
| Wessmann, A | 1 |
| Harcourt-Brown, T | 1 |
| Kluger, EK | 2 |
| Malik, R | 4 |
| Ilkin, WJ | 1 |
| Snow, D | 1 |
| Sullivan, DR | 1 |
| Govendir, M | 3 |
| Scorza, FA | 1 |
| Cavalheiro, EA | 1 |
| Arida, RM | 1 |
| Terra, VC | 1 |
| Scorza, CA | 1 |
| Ribeiro, MO | 1 |
| Cysneiros, RM | 1 |
| Kennerly, EM | 1 |
| Idaghdour, Y | 1 |
| Olby, NJ | 1 |
| Gibson, G | 1 |
| Monteiro, R | 1 |
| Anderson, TJ | 2 |
| Innocent, G | 1 |
| Evans, NP | 1 |
| Thomas, WB | 1 |
| Dewey, CW | 1 |
| Cerda-Gonzalez, S | 1 |
| Levine, JM | 1 |
| Badgley, BL | 1 |
| Ducoté, JM | 1 |
| Silver, GM | 1 |
| Cooper, JJ | 1 |
| Packer, RA | 1 |
| Lavely, JA | 1 |
| Brink, CJ | 1 |
| Gommeren, K | 1 |
| Claeys, S | 1 |
| de Rooster, H | 1 |
| Hamaide, A | 1 |
| Bevier, DE | 1 |
| Miller, MA | 1 |
| Rohleder, JJ | 1 |
| Wozniak, AD | 1 |
| Jambroszyk, M | 1 |
| Potschka, H | 2 |
| Davies, ES | 1 |
| Behr, S | 1 |
| Summers, B | 1 |
| de Lahunta, A | 1 |
| Syme, H | 1 |
| Jull, P | 1 |
| Borschensky, CM | 1 |
| Woolley, JS | 1 |
| Kipar, A | 1 |
| Herden, C | 1 |
| Boothe, DM | 1 |
| Dewey, C | 1 |
| Carpenter, DM | 1 |
| Boydell, P | 1 |
| Pike, R | 1 |
| Crossley, D | 1 |
| Whitbread, T | 1 |
| Finke, MD | 1 |
| Meola, SD | 1 |
| Mazzaferro, EM | 1 |
| McConkey, SE | 1 |
| Walker, S | 1 |
| Adams, C | 1 |
| Rossmeisl, JH | 1 |
| Jones, JC | 1 |
| Zimmerman, KL | 1 |
| Robertson, JL | 1 |
| Aitken, MM | 1 |
| Hall, E | 1 |
| Scott, L | 1 |
| Davot, JL | 1 |
| Allen, WM | 1 |
| Rieck, S | 1 |
| Dodman, NH | 4 |
| Cottam, N | 1 |
| Gaskill, CL | 5 |
| Hoffmann, WE | 2 |
| Cribb, AE | 5 |
| Miller, LM | 1 |
| Mattoon, JS | 1 |
| Burton, SA | 3 |
| Gelens, HC | 3 |
| Ihle, SL | 3 |
| Miller, JB | 3 |
| Shaw, DH | 3 |
| Perkins, M | 1 |
| Chang, Y | 1 |
| Mellor, DJ | 1 |
| Platt, SR | 2 |
| De Stefani, A | 1 |
| Wieczorek, L | 1 |
| Matiasek, LA | 1 |
| Luján Feliu-Pascual, A | 1 |
| Chandler, KE | 1 |
| Ashawesh, K | 1 |
| Abdulqawi, R | 1 |
| Ahmad, S | 1 |
| Territo, PR | 1 |
| Freise, KJ | 1 |
| Newhall, K | 1 |
| Barnhart, SD | 1 |
| Peters, SC | 1 |
| Engleking, DR | 1 |
| Burnett, TJ | 1 |
| Abdul-Karim, B | 1 |
| Shannon, HE | 1 |
| Kitagawa, M | 1 |
| Okada, M | 1 |
| Koie, H | 2 |
| Kanayama, K | 1 |
| Sakai, T | 2 |
| Bryant, SM | 1 |
| Mycyk, MB | 1 |
| Khoutorsky, A | 1 |
| Bruchim, Y | 1 |
| Farnbach, GC | 3 |
| Cunningham, JG | 1 |
| Haidukewych, D | 1 |
| Jensen, HA | 1 |
| Holliday, TA | 1 |
| Bunch, SE | 3 |
| Castleman, WL | 2 |
| Hornbuckle, WE | 2 |
| Tennant, BC | 2 |
| Skinner, SF | 1 |
| Robertson, LT | 1 |
| Artero, M | 1 |
| Gerding, RK | 1 |
| Chauvet, AE | 1 |
| Feldman, EC | 1 |
| Kass, PH | 1 |
| Dowling, PM | 2 |
| Bronson, R | 1 |
| Gliatto, J | 1 |
| Nichols, ES | 1 |
| Trepanier, LA | 6 |
| Linn, K | 1 |
| Shaw, N | 1 |
| Center, SA | 2 |
| Garland, S | 1 |
| Harris, LJ | 1 |
| Skaletsky, E | 1 |
| McPherson, A | 1 |
| Knowles, KE | 1 |
| Shuster, L | 2 |
| Moon-Fanelli, AA | 1 |
| Tidwell, AS | 1 |
| Keen, CL | 1 |
| Podell, M | 3 |
| Jaggy, A | 2 |
| Heynold, Y | 2 |
| Faissler, D | 1 |
| Steffen, F | 1 |
| Jacobs, G | 1 |
| Calvert, C | 1 |
| Kaufman, A | 1 |
| Knowles, K | 2 |
| Van Schoick, A | 1 |
| Schwark, WS | 1 |
| Carrillo, J | 1 |
| Lord, LK | 1 |
| Kantrowitz, LB | 1 |
| Peterson, ME | 1 |
| Melián, C | 1 |
| Nichols, R | 1 |
| Brimacombe, MB | 2 |
| Bateman, SW | 1 |
| Parent, JM | 1 |
| Foster, SF | 2 |
| Church, DB | 2 |
| Watson, AD | 2 |
| Milani, M | 1 |
| Vaughan-Scott, T | 1 |
| Taylor, JH | 1 |
| Kurotobi, EN | 1 |
| Levitski, RE | 1 |
| Melton, S | 1 |
| Stonehewer, J | 1 |
| Mackin, AJ | 1 |
| Tasker, S | 1 |
| Simpson, JW | 1 |
| Mayhew, IG | 1 |
| Tisdall, PL | 1 |
| Hunt, GB | 1 |
| Youmans, KR | 1 |
| Dugdale, AH | 1 |
| Lakhani, KH | 1 |
| Brearley, JC | 1 |
| Dunnett, M | 1 |
| Littleford, A | 1 |
| Lees, P | 1 |
| Culpin, PA | 1 |
| Miczek, KA | 1 |
| Thalhammer, JG | 1 |
| Dayrell-Hart, B | 1 |
| Steinberg, SA | 1 |
| VanWinkle, TJ | 1 |
| Schwartz-Porsche, D | 3 |
| Jürgens, U | 1 |
| Frey, HH | 3 |
| Morton, DJ | 1 |
| Honhold, N | 1 |
| Obe, G | 1 |
| Riedel, L | 1 |
| Barthel, A | 1 |
| Conway, MB | 1 |
| Baldwin, BH | 1 |
| Lannek, B | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Big Data Construction and Biological Etiological Epidemiology Study of Children Epilepsy in China[NCT02969213] | 10,000 participants (Anticipated) | Observational | 2016-11-30 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
9 reviews available for phenobarbital and Canine Diseases
| Article | Year |
|---|---|
Idiopathic epilepsy in dogs and cats.
Topics: Animals; Anticonvulsants; Bromides; Cat Diseases; Cats; Dog Diseases; Dogs; Dose-Response Relationsh | 2010 |
Seizure disorders.
Topics: Animals; Cat Diseases; Cats; Diagnosis, Differential; Diazepam; Dog Diseases; Dogs; Epilepsy; Mephob | 1980 |
Hepatotoxicity associated with pharmacologic agents in dogs and cats.
Topics: Animals; Anthelmintics; Benzimidazoles; Cat Diseases; Cats; Chemical and Drug Induced Liver Injury; | 1993 |
Seizures in dogs.
Topics: Animals; Anticonvulsants; Diagnosis, Differential; Diazepam; Dog Diseases; Dogs; Epilepsy; Phenobarb | 1996 |
[Idiopathic epilepsy in the dog].
Topics: Animals; Anticonvulsants; Breeding; Dog Diseases; Dogs; Electroencephalography; Epilepsy; Phenobarbi | 1996 |
Idiopathic epilepsy.
Topics: Age Factors; Animals; Anticonvulsants; Bromides; Cat Diseases; Cats; Diagnosis, Differential; Dog Di | 1998 |
Antiepileptic drug therapy.
Topics: Acetates; Amines; Animals; Anticonvulsants; Bromides; Cat Diseases; Cats; Cyclohexanecarboxylic Acid | 1998 |
Update on therapy of canine epilepsy.
Topics: Animals; Anticonvulsants; Bromides; Dog Diseases; Dogs; Dose-Response Relationship, Drug; Drug Monit | 1999 |
Pharmacokinetics of anti-epileptic drugs in the dog: a review.
Topics: Animals; Anticonvulsants; Blood Proteins; Carbamazepine; Clonazepam; Diazepam; Dog Diseases; Dogs; E | 1985 |
9 trials available for phenobarbital and Canine Diseases
| Article | Year |
|---|---|
Open-label clinical trial of rectally administered levetiracetam as supplemental treatment in dogs with cluster seizures.
Topics: Administration, Intravenous; Administration, Rectal; Animals; Anticonvulsants; Diazepam; Dog Disease | 2019 |
Clinical efficacy and safety of imepitoin in comparison with phenobarbital for the control of idiopathic epilepsy in dogs.
Topics: Animals; Anticonvulsants; Dog Diseases; Dogs; Dose-Response Relationship, Drug; Epilepsy; Imidazoles | 2015 |
A single-blinded phenobarbital-controlled trial of levetiracetam as mono-therapy in dogs with newly diagnosed epilepsy.
Topics: Animals; Anticonvulsants; Dog Diseases; Dogs; Epilepsy; Female; Levetiracetam; Male; Phenobarbital; | 2016 |
The effect of imepitoin, a recently developed antiepileptic drug, on thyroid parameters and fat metabolism in healthy Beagle dogs.
Topics: Animals; Anticonvulsants; Dog Diseases; Dogs; Epilepsy; Female; Imidazoles; Lipid Metabolism; Longit | 2016 |
Clinical evaluation of a combination therapy of imepitoin with phenobarbital in dogs with refractory idiopathic epilepsy.
Topics: Animals; Anticonvulsants; Cohort Studies; Dog Diseases; Dogs; Dose-Response Relationship, Drug; Drug | 2017 |
Phenobarbital or potassium bromide as an add-on antiepileptic drug for the management of canine idiopathic epilepsy refractory to imepitoin.
Topics: Animals; Anticonvulsants; Belgium; Bromides; Dog Diseases; Dogs; Epilepsy; Imidazoles; Phenobarbital | 2017 |
Pregabalin as an adjunct to phenobarbital, potassium bromide, or a combination of phenobarbital and potassium bromide for treatment of dogs with suspected idiopathic epilepsy.
Topics: Animals; Anticonvulsants; Bromides; Dog Diseases; Dogs; Drug Therapy, Combination; Epilepsy; Female; | 2009 |
Effect of phenobarbitone on the low-dose dexamethasone suppression test and the urinary corticoid: creatinine ratio in dogs.
Topics: Adrenal Cortex Function Tests; Adrenal Cortex Hormones; Animals; Anticonvulsants; Creatinine; Dexame | 2000 |
Effects of phenobarbitone on serum biochemical tests in dogs.
Topics: Alanine Transaminase; Alkaline Phosphatase; Animals; Anticonvulsants; Bilirubin; Blood Chemical Anal | 2000 |
105 other studies available for phenobarbital and Canine Diseases
| Article | Year |
|---|---|
Pancytopenia secondary to suspected idiosyncratic phenobarbital reaction in a dog.
Topics: Animals; Dog Diseases; Dogs; Male; Pancytopenia; Phenobarbital; Seizures | 2021 |
Approach to initial management of canine generalised epileptic seizures in primary-care veterinary practices in the United Kingdom.
Topics: Animals; Anticonvulsants; Dog Diseases; Dogs; Epilepsy; Phenobarbital; Seizures | 2022 |
Comparison of caregivers' assessments of clinical outcome in dogs with idiopathic epilepsy administered levetiracetam, zonisamide, or phenobarbital monotherapy.
Topics: Animals; Anticonvulsants; Caregivers; Dog Diseases; Dogs; Epilepsy; Humans; Levetiracetam; Phenobarb | 2023 |
Treatment of phenobarbital intoxication using hemodialysis in two dogs.
Topics: Animals; Dog Diseases; Dogs; Female; Hypnotics and Sedatives; Male; Phenobarbital; Renal Dialysis | 2020 |
Successful treatment of a dog with phenobarbital-responsive sialadenosis and an oesophageal stricture.
Topics: Animals; Catheterization; Dog Diseases; Dogs; Esophageal Stenosis; Phenobarbital; Salivary Gland Dis | 2021 |
Bone marrow, blood, and clinical findings in dogs treated with phenobarbital.
Topics: Anemia; Animals; Bone Marrow; Dog Diseases; Dogs; Hematologic Diseases; Phenobarbital | 2021 |
Serum NMR metabolomics uncovers multiple metabolic changes in phenobarbital-treated dogs.
Topics: Albumins; Animals; Cross-Sectional Studies; Dog Diseases; Dogs; Metabolomics; Phenobarbital | 2021 |
Daytime and nocturnal activity in treated dogs with idiopathic epilepsy compared to matched unaffected controls.
Topics: Animals; Anticonvulsants; Dog Diseases; Dogs; Epilepsy; Phenobarbital; Prospective Studies | 2021 |
Evaluation of the effect of phenobarbital administration on the biochemistry profile, with a focus on serum liver values, in epileptic cats.
Topics: Alanine Transaminase; Animals; Anticonvulsants; Cat Diseases; Cats; Dog Diseases; Dogs; Epilepsy; Fe | 2022 |
Cricopharyngeal dysphagia and phenobarbitone-responsive sialoadenosis in a Miniature Poodle.
Topics: Animals; Deglutition Disorders; Dog Diseases; Dogs; Fluoroscopy; Male; Phenobarbital; Sialadenitis | 2017 |
Suspected Phenobarbital-Induced Pseudolymphoma in a Dog.
Topics: Animals; Anticonvulsants; Dog Diseases; Dogs; Epilepsy; Levetiracetam; Male; Phenobarbital; Piraceta | 2017 |
Imepitoin withdrawal in dogs with idiopathic epilepsy well-controlled with imepitoin and phenobarbital and/or potassium bromide does not increase seizure frequency.
Topics: Animals; Anticonvulsants; Bromides; Dog Diseases; Dogs; Drug Therapy, Combination; Epilepsy; Female; | 2017 |
Population pharmacokinetics of extended-release levetiracetam in epileptic dogs when administered alone, with phenobarbital or zonisamide.
Topics: Animals; Anticonvulsants; Delayed-Action Preparations; Dog Diseases; Dogs; Drug Interactions; Epilep | 2018 |
An analytical strategy for the identification of carbamates, toxic alkaloids, phenobarbital and warfarin in stomach contents from suspected poisoned animals by thin-layer chromatography/ultraviolet detection.
Topics: Alkaloids; Animals; Carbamates; Cat Diseases; Cats; Chromatography, Thin Layer; Dog Diseases; Dogs; | 2019 |
Epileptic seizure frequency and semiology in dogs with idiopathic epilepsy after initiation of imepitoin or phenobarbital monotherapy.
Topics: Animals; Anticonvulsants; Cohort Studies; Dog Diseases; Dogs; Epilepsy; Imidazoles; Phenobarbital; P | 2019 |
Feasibility study of a caregiver seizure alert system in canine epilepsy.
Topics: Algorithms; Animals; Anticonvulsants; Caregivers; Chromatography, High Pressure Liquid; Clinical Ala | 2013 |
Switching between medications for the management of epilepsy in dogs.
Topics: Animals; Anticonvulsants; Dog Diseases; Dogs; Epilepsy; Phenobarbital | 2013 |
High frequency of a single nucleotide substitution (c.-6-180T>G) of the canine MDR1/ABCB1 gene associated with phenobarbital-resistant idiopathic epilepsy in Border Collie dogs.
Topics: Animals; Anticonvulsants; ATP Binding Cassette Transporter, Subfamily B, Member 1; Dog Diseases; Dog | 2013 |
L-2 hydroxyglutaric aciduria in a South African Staffordshire Bull Terrier.
Topics: Animals; Anticonvulsants; Brain Diseases, Metabolic, Inborn; Dog Diseases; Dogs; Female; Phenobarbit | 2014 |
Phenobarbitone-induced haematological abnormalities in idiopathic epileptic dogs: prevalence, risk factors, clinical presentation and outcome.
Topics: Animals; Anticonvulsants; Dog Diseases; Dogs; Epilepsy; Female; Hematologic Diseases; Male; Phenobar | 2014 |
Monitoring side effects of antiepileptic drugs.
Topics: Animals; Anticonvulsants; Dog Diseases; Epilepsy; Female; Hematologic Diseases; Male; Phenobarbital | 2014 |
Phenobarbital-responsive sialadenosis in dogs: case series.
Topics: Animals; Diagnosis, Differential; Dog Diseases; Dogs; Female; GABA Modulators; Male; Phenobarbital; | 2014 |
Addisonian crisis in a dog treated with phenobarbitone.
Topics: Acute Disease; Addison Disease; Animals; Anticonvulsants; Dog Diseases; Dogs; Epilepsy, Generalized; | 2015 |
What is your diagnosis? Liver aspirate from a hypoglycemic dog.
Topics: Abdomen; Animals; Anticonvulsants; Biopsy, Fine-Needle; Dog Diseases; Dogs; Euthanasia, Animal; Hypo | 2015 |
Canine Pancreas-Specific Lipase and C-reactive Protein in Dogs Treated With Anticonvulsants (Phenobarbital and Potassium Bromide).
Topics: Animals; Anticonvulsants; Bromides; C-Reactive Protein; Dog Diseases; Dogs; Epilepsy; Female; Lipase | 2015 |
Successful treatment of Solanum dulcamara intoxication in a Labrador retriever puppy.
Topics: Animals; Dog Diseases; Dogs; Hypnotics and Sedatives; Male; Methocarbamol; Muscle Relaxants, Central | 2015 |
Successful treatment of refractory seizures with phenobarbital, propofol, and medetomidine following congenital portosystemic shunt ligation in a dog.
Topics: Animals; Anticonvulsants; Diagnosis, Differential; Dog Diseases; Dogs; Drug Therapy, Combination; Ma | 2016 |
Lissencephaly in an adult Australian Kelpie.
Topics: Animals; Anticonvulsants; Cerebral Cortex; Dog Diseases; Dogs; Lissencephaly; Magnetic Resonance Ima | 2016 |
Presumed phenobarbital-induced Stevens-Johnson syndrome in a 4-year-old female Great Dane.
Topics: Animals; Anticonvulsants; Bromides; Dog Diseases; Dogs; Female; Phenobarbital; Potassium Compounds; | 2016 |
Comparing the effects of first-line antiepileptic drugs on the gait of dogs with idiopathic epilepsy.
Topics: Animals; Anticonvulsants; Ataxia; Case-Control Studies; Dog Diseases; Dogs; Epilepsy; Gait; Imidazol | 2016 |
Suspected phenobarbitone hypersensitivity with acute liver failure in a dog.
Topics: Animals; Anticonvulsants; Chemical and Drug Induced Liver Injury; Dog Diseases; Dogs; Drug Hypersens | 2017 |
Phenobarbital administration every eight hours: improvement of seizure management in idiopathic epileptic dogs with decreased phenobarbital elimination half-life.
Topics: Animals; Anticonvulsants; Dog Diseases; Dogs; Drug Administration Schedule; Epilepsy, Generalized; F | 2017 |
Phenobarbital - a beneficial eight-hourly dosing option?
Topics: Animals; Anticonvulsants; Dog Diseases; Dogs; Drug Administration Schedule; Epilepsy, Generalized; P | 2017 |
Anticonvulsant responsive, episodic movement disorder in a German shorthaired pointer.
Topics: Animals; Anticonvulsants; Bromides; Diagnosis, Differential; Dog Diseases; Dogs; Dyskinesias; Male; | 2008 |
Serum triglyceride concentration in dogs with epilepsy treated with phenobarbital or with phenobarbital and bromide.
Topics: Animals; Bromides; Case-Control Studies; Cross-Sectional Studies; Dog Diseases; Dogs; Epilepsy; Fast | 2008 |
Positive impact of omega-3 fatty acid supplementation in a dog with drug-resistant epilepsy: a case study.
Topics: Animals; Anticonvulsants; Behavior, Animal; Dietary Supplements; Dog Diseases; Dogs; Drug Resistance | 2009 |
Pharmacogenetic association study of 30 genes with phenobarbital drug response in epileptic dogs.
Topics: Animals; Anticonvulsants; Case-Control Studies; Dog Diseases; Dogs; Drug Resistance; Epilepsy; Pharm | 2009 |
Veterinarians' preferences for anticonvulsant drugs for treating seizure disorders in dogs and cats.
Topics: Animals; Anticonvulsants; Bromides; Cat Diseases; Cats; Cross-Sectional Studies; Dog Diseases; Dogs; | 2009 |
Variations in serum concentration of phenobarbitone in dogs receiving regular twice daily doses in relation to the times of administration.
Topics: Animals; Anticonvulsants; Dog Diseases; Dogs; Dose-Response Relationship, Drug; Drug Administration | 2009 |
[Phenobarbital].
Topics: Animals; Dog Diseases; Dogs; Epilepsy; Humans; Phenobarbital; Prescription Drugs | 2010 |
Outcome from status epilepticus after portosystemic shunt attenuation in 3 dogs treated with propofol and phenobarbital.
Topics: Animals; Anticonvulsants; Dog Diseases; Dogs; Female; Liver Diseases; Male; Phenobarbital; Portal Sy | 2010 |
Pathology in practice. Superficial necrolytic dermatitis.
Topics: Amino Acids; Animals; Anticonvulsants; Dog Diseases; Dogs; Drug Eruptions; Foot Diseases; Male; Phen | 2010 |
Add-on treatment with verapamil in pharmacoresistant canine epilepsy.
Topics: Age of Onset; Animals; Anticonvulsants; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blo | 2011 |
Porencephaly and hydranencephaly in six dogs.
Topics: Animals; Cerebellar Diseases; Cerebellum; Dog Diseases; Dogs; Female; Hydranencephaly; Male; Phenoba | 2012 |
Neurogenesis in a young dog with epileptic seizures.
Topics: Administration, Oral; Animals; Anticonvulsants; Autopsy; Case-Control Studies; Cell Differentiation; | 2012 |
Comparison of phenobarbital with bromide as a first-choice antiepileptic drug for treatment of epilepsy in dogs.
Topics: Animals; Anticonvulsants; Bromides; Dog Diseases; Dogs; Epilepsy; Female; Male; Phenobarbital; Time | 2012 |
Sialadenosis in dogs.
Topics: Animals; Dog Diseases; Dogs; GABA Modulators; Phenobarbital; Salivary Glands; Sialadenitis | 2000 |
Ascending tonic-clonic seizure syndrome in a dog following inadvertent intrathecal use of ionic contrast agent.
Topics: Animals; Anticonvulsants; Contrast Media; Diatrizoate; Diazepam; Dog Diseases; Dogs; Epilepsy, Tonic | 2012 |
Compounding errors in 2 dogs receiving anticonvulsants.
Topics: Animals; Anticonvulsants; Bromides; Dog Diseases; Dogs; Drug Compounding; Male; Medication Errors; P | 2012 |
Survival time following hospital discharge in dogs with palliatively treated primary brain tumors.
Topics: Animals; Brain Neoplasms; Dog Diseases; Dogs; Female; Male; Palliative Care; Phenobarbital; Predniso | 2013 |
Liver-related biochemical changes in the serum of dogs being treated with phenobarbitone.
Topics: Alanine Transaminase; Alkaline Phosphatase; Animals; Anticonvulsants; Chemical and Drug Induced Live | 2003 |
Anticonvulsant efficacy of the low-affinity partial benzodiazepine receptor agonist ELB 138 in a dog seizure model and in epileptic dogs with spontaneously recurrent seizures.
Topics: Animals; Anticonvulsants; Bromides; Chronic Disease; Disease Models, Animal; Dog Diseases; Dogs; Dru | 2004 |
Animal behavior case of the month. Two dogs were evaluated for episodic bouts of bizarre behavior.
Topics: Animals; Anticonvulsants; Behavior, Animal; Diagnosis, Differential; Dog Diseases; Dogs; Epilepsies, | 2004 |
Serum alkaline phosphatase isoenzyme profiles in phenobarbital-treated epileptic dogs.
Topics: Alkaline Phosphatase; Animals; Anticonvulsants; Cross-Sectional Studies; Dog Diseases; Dogs; Epileps | 2004 |
Liver histopathology and liver and serum alanine aminotransferase and alkaline phosphatase activities in epileptic dogs receiving phenobarbital.
Topics: Alanine Transaminase; Alkaline Phosphatase; Animals; Anticonvulsants; Chemical and Drug Induced Live | 2005 |
Improving seizure control in dogs with refractory epilepsy using gabapentin as an adjunctive agent.
Topics: Amines; Animals; Anticonvulsants; Bromides; Chemotherapy, Adjuvant; Cyclohexanecarboxylic Acids; Dog | 2005 |
Idiopathic epilepsy in dogs: owners' perspectives on management with phenobarbitone and/or potassium bromide.
Topics: Animals; Anticonvulsants; Bromides; Dog Diseases; Dogs; Drug Therapy, Combination; Epilepsy; Phenoba | 2006 |
Primary orthostatic tremor in a Scottish deerhound.
Topics: Amines; Animals; Cyclohexanecarboxylic Acids; Dog Diseases; Dogs; Electromyography; Excitatory Amino | 2006 |
The efficacy and tolerability of levetiracetam in pharmacoresistant epileptic dogs.
Topics: Animals; Anticonvulsants; Bromides; Dog Diseases; Dogs; Dose-Response Relationship, Drug; Drug Thera | 2008 |
Self-poisoning with pet medications.
Topics: Animals; Anticonvulsants; Dog Diseases; Dogs; Female; Humans; Middle Aged; Phenobarbital; Suicide, A | 2007 |
Development and validation of the maximal electro-shock seizure model in dogs.
Topics: Animals; Anticonvulsants; Area Under Curve; Disease Models, Animal; Dog Diseases; Dogs; Dose-Respons | 2007 |
Magnetic resonance imaging and computed tomography appearance of chronic subdural haematoma in a dog.
Topics: Animals; Anticonvulsants; Dog Diseases; Dogs; Female; Hematoma, Subdural, Chronic; Magnetic Resonanc | 2008 |
Response to self-poisoning with pet medications.
Topics: Animals; Anticonvulsants; Dog Diseases; Dogs; Drug Overdose; Humans; Phenobarbital; Suicide, Attempt | 2008 |
Transient leucopenia, thrombocytopenia and anaemia associated with severe acute phenobarbital intoxication in a dog.
Topics: Anemia; Animals; Anti-Anxiety Agents; Dog Diseases; Dogs; Leukopenia; Male; Phenobarbital; Thrombocy | 2008 |
Efficacy of primidone in dogs with seizures unresponsive to phenobarbital.
Topics: Animals; Dog Diseases; Dogs; Epilepsy; Female; Male; Phenobarbital; Primidone | 1984 |
Serum concentrations and efficacy of phenytoin, phenobarbital, and primidone in canine epilepsy.
Topics: Animals; Dog Diseases; Dogs; Drug Therapy, Combination; Epilepsy; Phenobarbital; Phenytoin; Primidon | 1984 |
Therapeutic serum concentrations of primidone and its metabolites, phenobarbital and phenylethylmalonamide in epileptic dogs.
Topics: Animals; Dog Diseases; Dogs; Epilepsy; Malonates; Phenobarbital; Phenylethylmalonamide; Primidone | 1983 |
Hepatic cirrhosis associated with long-term anticonvulsant drug therapy in dogs.
Topics: Animals; Anticonvulsants; Dog Diseases; Dogs; Female; Liver; Liver Cirrhosis; Male; Microscopy, Elec | 1982 |
Longitudinal study of phenobarbital in serum, cerebrospinal fluid, and saliva in the dog.
Topics: Animals; Dog Diseases; Dogs; Epilepsy; Phenobarbital; Saliva | 1980 |
Effects of phenobarbital administration on results of serum biochemical analyses and adrenocortical function tests in epileptic dogs.
Topics: Adrenal Cortex; Adrenal Cortex Function Tests; Adrenocorticotropic Hormone; Alanine Transaminase; Al | 1995 |
Management of canine epilepsy with phenobarbital and potassium bromide.
Topics: Algorithms; Animals; Bromides; Dog Diseases; Dogs; Drug Administration Schedule; Epilepsy; Phenobarb | 1994 |
Tail chasing in a bull terrier.
Topics: Aggression; Animals; Behavior, Animal; Diazepam; Dog Diseases; Dogs; Electroencephalography; Epileps | 1993 |
Bromide toxicosis secondary to renal insufficiency in an epileptic dog.
Topics: Animals; Anticonvulsants; Bromides; Creatinine; Diuresis; Dog Diseases; Dogs; Drug Therapy, Combinat | 1996 |
High dietary chloride content associated with loss of therapeutic serum bromide concentrations in an epileptic dog.
Topics: Animals; Anticonvulsants; Bromides; Chlorides; Diet; Dog Diseases; Dogs; Epilepsy; Female; Liver; Ph | 1996 |
Crystallization of intact monoclonal antibodies.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Neoplasm; Antibody Specificity; Crystallization; Crysta | 1995 |
Behavioral changes associated with suspected complex partial seizures in bull terriers.
Topics: Animals; Anticonvulsants; Behavior, Animal; Brain; Breeding; Dog Diseases; Dogs; Electroencephalogra | 1996 |
Clinical, epidemiological and treatment results of idiopathic epilepsy in 54 labrador retrievers: a long-term study.
Topics: Administration, Oral; Animals; Anticonvulsants; Dog Diseases; Dogs; Epilepsy; Female; Follow-Up Stud | 1997 |
Neutropenia and thrombocytopenia in three dogs treated with anticonvulsants.
Topics: Anemia; Animals; Anticonvulsants; Bacteremia; Blood Cell Count; Dog Diseases; Dogs; Female; Male; Ne | 1998 |
Therapeutic serum drug concentrations in epileptic dogs treated with potassium bromide alone or in combination with other anticonvulsants: 122 cases (1992-1996).
Topics: Animals; Anticonvulsants; Bromides; Dog Diseases; Dogs; Drug Therapy, Combination; Epilepsy; Follow- | 1998 |
Owner perception of the care of long-term phenobarbital-treated epileptic dogs.
Topics: Adult; Animals; Anticonvulsants; Dog Diseases; Dogs; Epilepsy; Female; Humans; Life Style; Male; Pat | 1999 |
Serum total thyroxine, total triiodothyronine, free thyroxine, and thyrotropin concentrations in epileptic dogs treated with anticonvulsants.
Topics: Animals; Anticonvulsants; Bromides; Dog Diseases; Dogs; Drug Therapy, Combination; Epilepsy; Female; | 1999 |
Effects of phenobarbital treatment on serum thyroxine and thyroid-stimulating hormone concentrations in epileptic dogs.
Topics: Alanine Transaminase; Alkaline Phosphatase; Animals; Anticonvulsants; Aspartate Aminotransferases; B | 1999 |
Clinical findings, treatment, and outcome of dogs with status epilepticus or cluster seizures: 156 cases (1990-1995).
Topics: Animals; Anticonvulsants; Bromides; Cerebrospinal Fluid; Diazepam; Dog Diseases; Dogs; Female; Male; | 1999 |
Recommends integrated approach to diagnosis and treatment.
Topics: Animals; Behavior, Animal; Dog Diseases; Dogs; Phenobarbital; Salivary Gland Diseases | 2000 |
Drug choice and therapeutic drug monitoring in the management of canine primary epilepsy.
Topics: Animals; Anticonvulsants; Bromides; Dog Diseases; Dogs; Drug Monitoring; Drug Therapy, Combination; | 1999 |
Pancreatitis associated with potassium bromide/phenobarbital combination therapy in epileptic dogs.
Topics: Animals; Anticonvulsants; Bromides; Dog Diseases; Dogs; Drug Interactions; Drug Therapy, Combination | 2000 |
Double-chambered right ventricle in a dog.
Topics: Animals; Anti-Bacterial Agents; Anticonvulsants; Antihypertensive Agents; Chloramphenicol; Dog Disea | 2000 |
Effect of timing of blood collection on serum phenobarbital concentrations in dogs with epilepsy.
Topics: Administration, Oral; Animals; Anticonvulsants; Blood Specimen Collection; Dog Diseases; Dogs; Epile | 2000 |
Error in dosage for phenobarbital.
Topics: Animals; Anticonvulsants; Dog Diseases; Dogs; Epilepsy; Medication Errors; Phenobarbital | 2000 |
Idiopathic phenobarbital-responsive hypersialosis in the dog: an unusual form of limbic epilepsy?
Topics: Animals; Anticonvulsants; Dog Diseases; Dogs; Epilepsy; Female; Limbic System; Male; Phenobarbital; | 2000 |
Changes in serum thyroxine and thyroid-stimulating hormone concentrations in epileptic dogs receiving phenobarbital for one year.
Topics: Analysis of Variance; Animals; Anticonvulsants; Dog Diseases; Dogs; Epilepsy; Female; Male; Phenobar | 2000 |
Neurological dysfunction in dogs following attenuation of congenital extrahepatic portosystemic shunts.
Topics: Animals; Anticonvulsants; Dog Diseases; Dogs; Female; Ligation; Male; Nervous System Diseases; Pheno | 2000 |
Thiopentone induction dose requirement in dogs is little influenced by co-administration of diazepam or prior treatment with phenobarbitone or corticosteroids, but is reduced in the presence of brain pathology.
Topics: Adrenal Cortex Hormones; Anesthesia, Intravenous; Animals; Brain Diseases; Diazepam; Dog Diseases; D | 2001 |
Phenobarbitone concentrations in the hair, saliva and plasma of eight epileptic dogs.
Topics: Animals; Anticonvulsants; Dog Diseases; Dogs; Dose-Response Relationship, Drug; Epilepsy; Hair; Phen | 2002 |
Anaesthetic death in a four-and-a-half-year-old Alsation.
Topics: Anesthesia, Intravenous; Animals; Dog Diseases; Dogs; Female; Heart Arrest; Phenobarbital; Phenytoin | 1978 |
Phenobarbital-responsive episodic dyscontrol (rage) in dogs.
Topics: Aggression; Animals; Behavior, Animal; Dog Diseases; Dogs; Electroencephalography; Epilepsy, Tempora | 1992 |
Bromism.
Topics: Animals; Bromides; Dog Diseases; Dogs; Drug Therapy, Combination; Phenobarbital; Potassium; Potassiu | 1992 |
Hepatotoxicity of phenobarbital in dogs: 18 cases (1985-1989).
Topics: Animals; Chemical and Drug Induced Liver Injury; Dog Diseases; Dogs; Female; Liver; Liver Diseases; | 1991 |
[Effectiveness of bromide in therapy resistant epilepsy of dogs].
Topics: Animals; Bromides; Dog Diseases; Dogs; Dose-Response Relationship, Drug; Drug Resistance; Epilepsy; | 1991 |
Use of anticonvulsants in small animals.
Topics: Animals; Anticonvulsants; Cat Diseases; Cats; Dog Diseases; Dogs; Epilepsy; Epilepsy, Tonic-Clonic; | 1986 |
Effectiveness of a therapeutic drug monitoring service as an aid to the control of canine seizures.
Topics: Animals; Dog Diseases; Dogs; Epilepsy; Female; Male; Phenobarbital; Primidone | 1988 |
[Cytogenetic analysis of lymphocytes from epileptic dogs].
Topics: Animals; Anticonvulsants; Chromosome Aberrations; Dog Diseases; Dogs; Epilepsy; Lymphocytes; Phenoba | 1987 |
Toxic hepatopathy and intrahepatic cholestasis associated with phenytoin administration in combination with other anticonvulsant drugs in three dogs.
Topics: Animals; Anticonvulsants; Chemical and Drug Induced Liver Injury; Cholestasis, Intrahepatic; Dog Dis | 1987 |
Therapeutic efficacy of phenobarbital and primidone in canine epilepsy: a comparison.
Topics: Animals; Dog Diseases; Dogs; Epilepsy; Phenobarbital; Primidone | 1985 |
Toxicity of halogenated oxyquinolines in dogs. A clinical study. II. History, symptoms, laboratory findings, therapy, and follow-up.
Topics: Animals; Chemical and Drug Induced Liver Injury; Dehydration; Dog Diseases; Dogs; Electrocardiograph | 1974 |